Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck
“We are very proud that, after a highly competitive selection process, Merck has chosen Diaccurate to bring DIACC3010 into advanced clinical development”, said Dominique Bridon, Ph.D., CEO of Diaccurate.
-
DIACC3010, formerly M2698, is a Phase II-ready dual PAM inhibitor with rare brain-penetration properties
-
Merck to become a shareholder of Diaccurate, remains fully committed to the success of the drug candidate
-
Diaccurate to start exploratory Phase II programs in incurable solid tumors and lymphomas by H2 2022
-
Acquisition broadens Diaccurate’s sole-in-class oncology and immunotherapy product pipeline and transforms it into a clinical−stage biotech mpany